Events are FREE to qualified industry participants and decision-makers.
Events are FREE to qualified industry participants and decision-makers.
Signed in as:
filler@godaddy.com
Pharma Shifts to Biologics Opening Remarks
Parrish Galliher (life science innovator, consultant w/BDO) and moderator Ben Locwin (executive, Black Diamond Networks) discuss how a large, well-established biotech company with an expanding pipeline addressed the technology and process requirements to support the necessary increase in production capacit
Ron Bates (vice president, development and manufacturing, Immunovant) and Ben Locwin (executive, Black Diamond Networks) discuss how a small biotech small company with a low-demand Fc fusion protein identified, where addressed, and how then implemented a strategy to overcome PPQ failu
Mark Petrich (vice president, technical operations, Krystal Biotech) and Ben Locwin (executive, Black Diamond Networks) discuss how material supply challenges can impact every biotech, large or small, equally - you either have what you need or you don't. However, there are proactive strategies your company can implement to avoid or reduce delays caused by supply bottlenecks.
Dave Backer (chief commercial officer, Oxford Biomedica) and moderator Ben Locwin (executive, Black Diamond Networks) discuss the stark technology and process similarities and differences between cell/gene therapies and mAbs and the lessons that can be applied to accelerate AAV production and scale.
Parrish Galliher (independent industry consultant) and Ben Locwin (executive, Black Diamond Networks) discuss how a small biotech start-up leveraged technology to accelerate production to compete with large biotech in the race to the clinic.
Dave Backer (chief commercial officer, Oxford Biomedica) and moderator Ben Locwin (executive Black Diamond Networks) discuss how the diversified and complex CGT market, currently in fed batch mode, is eyeing perfusion (where appropriate) is also experimenting with dedicated up/downstream technologies to improve recovery rates.
Pharma Shifts to Biologics Closing Remarks
Copyright © 2022 Evaluating Biopharma Events - All Rights Reserved.
Powered by GoDaddy Website Builder
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.